Sprint Bioscience

19/12/2025

Sprint Bioscience, represented by CEO Johan Emilsson, is attending JPM Week 2026 in San Francisco, January 12–15.

is the flagship gathering of the year for the global life science community – a full week of partnering, investor meetings, and groundbreaking ideas. We’re ready to showcase what’s next in oncology innovation.

We look forward to presenting Sprint Bioscience’s cutting-edge programs and exploring strategic collaborations that accelerate cancer drug development.

📍 Interested in connecting? Reach out via https://letspartner.bio.org/ Let’s discuss how we can partner!

25/11/2025

Sprint Biosciene CEO, Johan Emilsson, was invited to EFN Ekonomikanalen to discuss the transformative agreement with Gilead Sciences, where Sprint Bioscience divested its cancer program TREX1.

This deal is a strong validation of our world-class research and a significant step forward, not just for Sprint Bioscience, but for the entire Swedish industry.

Johan shared insights on what this partnership means for our pipeline and how it positions Sprint Bioscience for continued growth and innovation in oncology drug discovery.

🎥 Watch the full interview on EFN (in Swedish): https://efn.se/play/sprint-rusar-efter-affaren-med-gilead-det-hander-nu

Sprint rusar efter affären med Gilead – det händer nu| Håll dig uppdaterad med aktuella ekonominyheter – gratis.

24/11/2025

Sprint Bioscience today announced the sale of our TREX1 cancer program to Gilead Sciences, Inc. The agreement includes an upfront payment of USD 14 million, as well as potential clinical, regulatory, and commercial milestone payments totaling up to USD 400 million.
“We are pleased to enter into this agreement with Gilead, whom we value highly as a business partner. We appreciate their forward-looking approach and strong commitment to cutting-edge pharmaceutical development. TREX1 has demonstrated significant potential in the pre-clinical phase, and our decision to sell the program, rather than license it, reflects a strategic shift toward more flexible, value-driven exit opportunities,” said Emilsson, CEO of Sprint Bioscience.
Press release to be found here➡️
English: https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-sells-the-trex1-program-to-gilead
Swedish: https://sprintbioscience.com/sv/pressmeddelande/?slug=sprint-bioscience-saljer-trex1-programmet-till-gilead

14/10/2025

Sprint Bioscience is pleased to be in Gothenburg for Nordic Life Science Days – a key meeting point where innovation, partnerships, and the future of health take center stage. Our CEO Johan Emilsson and CSO Martin Andersson are on site, engaging in one-to-one meetings and discussions that help shape the next chapter in life science.

A special thank you to the Flemingsberg team Life Science Cluster Flemingsberg & Stiftelsen Flemingsberg Science for hosting us in their vibrant and welcoming booth (complete with a selfie machine 📸) – a space that truly reflects the energy and creativity of the region. Flemingsberg, Huddinge, is where we have our labs and conduct our everyday work. 🧪 🔬 🧫 💻
Last but not least - thank you SwedenBIO for a well-executed event.

12/09/2025

Sprint Bioscience report from Singapore: as part of the Swedish delegation engaging with key Life Science stakeholders, we had the opportunity to connect with leading research institutes, governmental agencies as well as local investors.
A highlight of the trip was a visit to our collaboration partner, Experimental Drug Development Centre (EDDC), which was especially memorable. We were also very proud to represent the Sweden–Singapore link at a reception hosted by Embassy of Sweden, Singapore – thank you for the warm welcome.
As always, we are grateful for the excellent support and guidance from SwedenBIO, Business Sweden, Swecare and Vinnova – thank you!
In connection with the delegation trip, we participated in the Asia Bio Partnering Forum by EBD Group, where we had the pleasure of engaging with both familiar and new members of our vibrant Life Science community.

26/06/2025

Sprint Bioscience is proud to announce that groundbreaking results from our DCPS program have been published in Leukemia, a leading journal in hematology and oncology from Nature. 📖 https://doi.org/10.1038/s41375-025-02661-z
The article highlights DCPS as a promising therapeutic target in Acute Myeloid Leukemia (AML). These findings pave the way for more precise patient selection and improved treatment outcomes, while maintaining a favorable safety profile.

This publication is the result of a strong collaboration with Karolinska Institutet, NeoTargets AB Julian Walfridsson, BioReperia, and support from the Swedish Foundation for Strategic Research: Stiftelsen för strategisk forskning, SSF has partially funded it through an industrial PhD fellowship.
A great step forward in our quest to make a difference for those affected by cancers such as AML.

Press release ➡️https://sprintbioscience.com/en/press-release/?slug=sprint-biosciences-dcps-data-published-in-leukemia
Sprint Bioscience team📸

25/06/2025

We’re proud to share a highlight of Vladimir Talibov, Associate Principal Scientist, Protein Science, Sprint Bioscience, who had the possibility to attend and present at Discovery & Development Europe 2025 summit in Basel ➡️ https://oxfordglobal.com/discovery-development/events/discovery-development-europe.

As part of the Hit Identification & Screening track, Vladimir delivered a compelling presentation titled ▪️“Leveraging Coupled Equilibrium in Fragment Screening”.

This talk explored innovative strategies in fragment-based drug discovery, emphasizing how coupled equilibrium can enhance screening efficiency and lead to more robust hit identification — a critical step in early-stage drug development.

A big thank you to the organizers at Oxford Global Conferences for creating a platform for knowledge exchange and innovation in biopharma R&D.

19/06/2025

Sprint Bioscience is proud to announce a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore regarding the therapeutic expansion of one of our programmes into inflammatory diseases.

“We are very pleased that our programme is attracting interest in inflammatory conditions as well, and excited at the potential to help patients with various inflammatory and autoimmune diseases. Given Sprint Bioscience’s focus on oncology, we see this collaboration as an excellent opportunity to gain access to the expertise required to evaluate these opportunities, thereby maximising the value of the programme,” says Johan Emilsson, CEO of Sprint Bioscience.

Full press release with more information about EDDC and the collaboration ➡️ https://sprintbioscience.com/en/press-release/?slug=sprint-bioscience-collaborates-to-expand-its-mash-programme-into-inflammation

This collaboration reflects our commitment to advancing innovative science and addressing unmet medical needs through strategic global partnerships.

17/06/2025

Sprint Bioscience is proud to be represented at . As always, one-to-one meetings and high-energy networking are keeping our leadership trio 📸 CEO Johan Emilsson, CBO Anne-Marie Wenthzel, and CSO Martin Andersson, busy. The first days of the convention have already shown the power of collaboration in biotech – and we’re here to connect with partners who share our vision for advancing science to deliver tangible benefits for patients. We are pleased to engage with both longstanding colleagues and new connections within the global biotech community.
Biotechnology Innovation Organization has organized an outstanding convention!

12/06/2025

The Sprint Bioscience team with, Johan Emilsson Anne-Marie Wenthzel Martin Andersson, are ready to meet you at in Boston next week.
As the world’s largest biotech gathering, BIO International Convention brings together 20,000 global leaders to shape the future of healthcare. It’s where innovation meets opportunity — and where we’ll be ready to connect.
The schedule is almost filled, but there’s still time to request a meeting through the partnering system ➡️ https://partner.bio.org/conference/68/search?keyword=Sprint&searchedTile=companies&sortBy=relevancy
Let’s explore new possibilities in oncology and drug development together.

04/06/2025

At Sprint Bioscience, we’re proud to collaborate with SciLifeLab and the SciLifeLab Drug Discovery & Development (DDD) Platform to enhance the speed and precision of our fragment-based drug discovery efforts. By leveraging SciLifeLab’s intact mass analysis capabilities, we gain rapid and reliable verification of protein batch identity—an essential step in our workflow.

“When we need to confirm that a newly purified protein batch is correct and consistent, we can’t afford to wait. That’s where SciLifeLab has been invaluable,” — Camilla Silvander, Director of Protein Science, Sprint Bioscience

This collaboration has also helped SciLifeLab expand its services:

“Sprint Bioscience played a key role in confirming the demand for intact mass determination in drug discovery workflows,” — Pawel Baranczewski, Head of the ADME of Therapeutics Unit, DDD Platform

Discover the full story at SciLifeLab's website ➡️ https://www.scilifelab.se/news/industry-case-sprint-bioscience-uses-scilifelab-infrastructure-to-accelerate-early-cancer-drug-development/

With a focus on speed, precision, and early innovation, Sprint Bioscience is developing small-molecule therapies for cancer. By partnering with SciLifeLab’s Drug Discovery and Development (DDD) Platform, the Stockholm-based biotech […]

09/05/2025

Sprint Bioscience has announced the outcome of the Rights Issue, which will provide the company with approximately SEK 23.4 million before costs. The issue was subscribed to approximately 74 percent, of which about 41 percent was subscribed with subscription rights, just under 2 percent without subscription rights, and the remaining 31 percent was allocated to the guarantors. Sprint Bioscience’s largest shareholder First Venture https://www.first-venture.se/ increased its participation compared to previous communication and subscribed for shares corresponding to SEK 4.3 million (SEK 3.0 million).

We welcome Life Science Invest Fund https://www.lsif.dk/, as a new owner. Through their participation as a guarantor, LSIF is now one of the company's five largest shareholders.

We would like to thank everyone who contributed to the issue. Together, we look forward – thank you for your continued trust!

In connection with the issue, Sprint Bioscience has engaged Sedermera Corporate Finance as financial advisor Fredersen Advokatbyrå as legal advisor and Nordic Issuing as issuing agent.

All information regarding the right issue is available on our website: https://sprintbioscience.com/sv/foretradesemission/foretradesemission-2025/